Golden Eye Antibiotic

Golden Eye Antibiotic is an ocular formulation containing the antibiotic chloramphenicol. It is marketed in the European Union and supplied as a sterile eye preparation for topical use. The product delivers chloramphenicol at a therapeutic concentration designed to treat bacterial eye infections. As a member of the amphenicol class, it works by inhibiting bacterial protein synthesis. This description provides a factual overview without dosage specifics.

Golden Eye Antibiotic is indicated for the treatment of bacterial infections of the eye surface. It is commonly prescribed when a clinician suspects or confirms bacterial conjunctivitis or other ocular infections caused by susceptible organisms.

- Bacterial conjunctivitis caused by susceptible strains of Staphylococcus, Streptococcus, Haemophilus, and Moraxella species. - Acute bacterial keratitis when topical therapy is appropriate. - Post‑operative prophylaxis of bacterial contamination after eye surgery. - External ocular infections such as blepharitis or superficial corneal ulcers. - Adjunctive therapy for mixed bacterial‑viral eye infections where bacterial component requires coverage.

The ocular use of chloramphenicol may be associated with a range of local and systemic adverse effects, although most are mild and reversible.

Common: - Transient eye irritation or burning sensation after instillation. - Mild conjunctival redness or hyperemia. - Temporary blurred vision that resolves within minutes. - Mild eyelid edema. - Slight increase in tear production or watery eyes. - Mild itching of the eyelid margin. - Temporary photophobia.

Serious: - Corneal epithelial toxicity leading to ulceration. - Allergic contact dermatitis of the peri‑ocular skin. - Rare systemic bone marrow suppression with prolonged use. - Development of resistant bacterial strains with inappropriate use. - Systemic adverse reactions such as nausea if absorbed in large amounts.

When prescribing Golden Eye Antibiotic, clinicians should consider several precautionary measures to minimize risks and ensure appropriate use.

- Verify that the ocular infection is bacterial and susceptible to chloramphenicol before initiating therapy. - Avoid use in patients with a known hypersensitivity to chloramphenicol or other amphenicols. - Limit treatment duration to the shortest effective period to reduce the chance of resistance. - Exercise caution in patients with pre‑existing corneal epithelial defects or severe dry eye. - Do not use in contact lens wearers unless lenses are removed and proper hygiene is maintained. - Consider alternative agents in pregnant or nursing individuals due to limited safety data.

Chloramphenicol eye drops can interact with other ophthalmic or systemic agents, influencing efficacy or safety.

Avoid: - Concurrent use with other topical antibiotics that have overlapping spectra, as this may increase risk of resistance. - Simultaneous administration of mydriatic or cycloplegic drops that could alter drug distribution on the ocular surface.

Use with caution: - Systemic aminoglycosides or other ototoxic drugs, because chloramphenicol may potentiate ototoxicity if absorbed. - Topical corticosteroids, which may mask signs of infection and delay healing. - Antifungal eye preparations, as combined use may affect corneal healing. - Non‑steroidal anti‑inflammatory eye drops, as they may reduce chloramphenicol penetration.